- Home
- SM vs DNLI Comparison
SM vs DNLI Comparison
Compare SM & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SM
- DNLI
- Stock Information
- Founded
- SM 1908
- DNLI 2013
- Country
- SM United States
- DNLI United States
- Employees
- SM N/A
- DNLI N/A
- Industry
- SM Oil & Gas Production
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SM Energy
- DNLI Health Care
- Exchange
- SM Nasdaq
- DNLI Nasdaq
- Market Cap
- SM 2.4B
- DNLI 2.2B
- IPO Year
- SM 1992
- DNLI 2017
- Fundamental
- Price
- SM $17.85
- DNLI $14.89
- Analyst Decision
- SM Hold
- DNLI Strong Buy
- Analyst Count
- SM 10
- DNLI 13
- Target Price
- SM $37.25
- DNLI $32.64
- AVG Volume (30 Days)
- SM 3.3M
- DNLI 1.5M
- Earning Date
- SM 11-03-2025
- DNLI 11-03-2025
- Dividend Yield
- SM 4.48%
- DNLI N/A
- EPS Growth
- SM N/A
- DNLI N/A
- EPS
- SM 6.33
- DNLI N/A
- Revenue
- SM $3,166,699,000.00
- DNLI N/A
- Revenue This Year
- SM $33.20
- DNLI N/A
- Revenue Next Year
- SM N/A
- DNLI $94,232.03
- P/E Ratio
- SM $2.82
- DNLI N/A
- Revenue Growth
- SM 35.48
- DNLI N/A
- 52 Week Low
- SM $17.83
- DNLI $10.57
- 52 Week High
- SM $46.42
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- SM 23.05
- DNLI 42.69
- Support Level
- SM $20.30
- DNLI $15.53
- Resistance Level
- SM $20.96
- DNLI $17.02
- Average True Range (ATR)
- SM 0.84
- DNLI 0.75
- MACD
- SM -0.16
- DNLI -0.22
- Stochastic Oscillator
- SM 0.22
- DNLI 10.44
About SM SM Energy Company
SM Energy Co is an independent energy company engaged in the acquisition, exploration, development, and production of oil, gas, and NGLs in Texas and Utah. Its portfolio is comprised of assets in the Midland Basin of West Texas, the Maverick Basin of South Texas, and the Uinta Basin of northeastern Utah.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.